Danaher Will Provide Cepheid's Xpert MTB/RIF Ultra Diagnostic Test Cartridges For Tuberculosis At Cepheid's Cost Of $7.97 Each To The Global Fund To Fight Aids, TB, And Malaria And To Less-developed Countries Eligible For Cepheid's Global Access Program
Portfolio Pulse from Benzinga Newsdesk
Danaher Corporation will supply Cepheid's Xpert MTB/RIF Ultra diagnostic test cartridges for tuberculosis at Cepheid's cost of $7.97 each to The Global Fund to Fight Aids, TB, and Malaria and to less-developed countries eligible for Cepheid's Global Access Program.
September 19, 2023 | 11:53 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Danaher's decision to provide Cepheid's diagnostic test cartridges at cost may not directly impact its short-term profits but could enhance its corporate image and potentially open up future opportunities in less-developed markets.
While this move by Danaher may not directly contribute to immediate profits, it could enhance the company's reputation for corporate responsibility. This could potentially lead to increased goodwill and trust among stakeholders, and open up opportunities in less-developed markets in the future.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100